Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Melero
SOLAR1, NCT05662397: A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody	Active, not recruiting	1/2	77	Europe, Canada, US	HST-1011, CBL-B inhibitor, Cemiplimab, anti-PD1 antibody	HotSpot Therapeutics, Inc	Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer	12/25	12/26